C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys New Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,712 shares of the company’s stock, valued at approximately $104,000.

Other large investors have also modified their holdings of the company. Stifel Financial Corp raised its stake in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after purchasing an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,218 shares in the last quarter. Sio Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $24,314,000. Finally, CWA Asset Management Group LLC acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $3,340,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent research reports. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $23.57.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $17.02 on Friday. The stock’s fifty day moving average is $19.92 and its 200-day moving average is $18.48. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a market capitalization of $19.28 billion, a PE ratio of -11.73, a PEG ratio of 1.34 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.